These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38401410)

  • 1. Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.
    Mäkipelto V; Tuulio-Henriksson A; Hakulinen C; Niemelä S; Lähteenvuo M; Wegelius A; Kieseppä T; Isometsä E; Tiihonen J; Kampman O; Lahdensuo K; Mazumder A; Suvisaari J; Holm M
    Schizophr Res; 2024 Apr; 266():118-126. PubMed ID: 38401410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic Burden and Cognition in Older Patients With Schizophrenia.
    Tsoutsoulas C; Mulsant BH; Kumar S; Ghazala Z; Voineskos AN; Menon M; Pollock BG; Rajji TK
    J Clin Psychiatry; 2017; 78(9):e1284-e1290. PubMed ID: 29188908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.
    Joshi YB; Thomas ML; Braff DL; Green MF; Gur RC; Gur RE; Nuechterlein KH; Stone WS; Greenwood TA; Lazzeroni LC; MacDonald LR; Molina JL; Nungaray JA; Radant AD; Silverman JM; Sprock J; Sugar CA; Tsuang DW; Tsuang MT; Turetsky BI; Swerdlow NR; Light GA
    Am J Psychiatry; 2021 Sep; 178(9):838-847. PubMed ID: 33985348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.
    Ang MS; Abdul Rashid NA; Lam M; Rapisarda A; Kraus M; Keefe RSE; Lee J
    J Clin Psychopharmacol; 2017 Dec; 37(6):651-656. PubMed ID: 29016375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term anticholinergic, benzodiazepine and Z-drug use in community-dwelling older adults: What is the impact on cognitive and neuropsychological performance?
    Dyer AH; Laird E; Hoey L; Hughes CF; McNulty H; Ward M; Strain JJ; Molloy AM; Cunningham C; McCarroll K
    Int J Geriatr Psychiatry; 2021 Nov; 36(11):1767-1777. PubMed ID: 34227695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive burden of anticholinergic medications in psychotic disorders.
    Eum S; Hill SK; Rubin LH; Carnahan RM; Reilly JL; Ivleva EI; Keedy SK; Tamminga CA; Pearlson GD; Clementz BA; Gershon ES; Keshavan MS; Keefe RSE; Sweeney JA; Bishop JR
    Schizophr Res; 2017 Dec; 190():129-135. PubMed ID: 28390849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia.
    Chan SKW; Pang TSW; Tsui HKH; Suen YN; Yan WC; Tsui CF; Poon LT; Chan CWH; Lo A; Cheung KM; Hui CLM; Chang WC; Lee EHM; Chen EYH; Honer WG
    Psychiatry Res; 2024 Jul; 337():115985. PubMed ID: 38820652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifetime use of psychiatric medications and cognition at 43years of age in schizophrenia in the Northern Finland Birth Cohort 1966.
    Hulkko AP; Murray GK; Moilanen J; Haapea M; Rannikko I; Jones PB; Barnett JH; Huhtaniska S; Isohanni MK; Koponen H; Jääskeläinen E; Miettunen J
    Eur Psychiatry; 2017 Sep; 45():50-58. PubMed ID: 28728095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anticholinergic burden on brain activity during Working Memory and real-world functioning in patients with schizophrenia.
    Selvaggi P; Fazio L; Toro VD; Mucci A; Rocca P; Martinotti G; Cascino G; Siracusano A; Zeppegno P; Pergola G; Bertolino A; Blasi G; Galderisi S;
    Schizophr Res; 2023 Oct; 260():76-84. PubMed ID: 37633126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.
    Vinogradov S; Fisher M; Warm H; Holland C; Kirshner MA; Pollock BG
    Am J Psychiatry; 2009 Sep; 166(9):1055-62. PubMed ID: 19570929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse of first-episode schizophrenia patients and neurocognitive impairment: The role of dopaminergic and anticholinergic burden.
    Cuesta MJ; Ballesteros A; Sánchez-Torres AM; Amoretti S; López-Ilundain JM; Merchán-Naranjo J; González-Ortega I; Salgado P; Rodriguez-Jimenez R; Roldán-Bejarano A; Sarró S; Ibáñez Á; Usall J; Escartí MJ; Moreno-Izco L; Mezquida G; Parellada M; González-Pinto A; Berrocoso E; Bernardo M;
    Schizophr Res; 2022 Oct; 248():331-340. PubMed ID: 36155307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study.
    O'Reilly K; O'Connell P; Donohoe G; Coyle C; O'Sullivan D; Azvee Z; Maddock C; Sharma K; Sadi H; McMahon M; Kennedy HG
    Psychol Med; 2016 Nov; 46(15):3199-3211. PubMed ID: 27576609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial.
    Lees J; Michalopoulou PG; Lewis SW; Preston S; Bamford C; Collier T; Kalpakidou A; Wykes T; Emsley R; Pandina G; Kapur S; Drake RJ
    Psychol Med; 2017 Oct; 47(13):2358-2368. PubMed ID: 28464963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia.
    Kim SJ; Jung D; Shim JC; Moon JJ; Jeon DW; Kim YN; Seo YS; Jung SS; Seo BJ; Kim JE
    Asian J Psychiatr; 2019 Dec; 46():111-117. PubMed ID: 31654923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling cognitive impairment in treatment-resistant schizophrenia patients.
    Frydecka D; Beszłej JA; Gościmski P; Kiejna A; Misiak B
    Psychiatry Res; 2016 Jan; 235():133-8. PubMed ID: 26706131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study.
    Ziad A; Berr C; Ruiz F; Bégaud B; Lemogne C; Goldberg M; Zins M; Mura T
    Drug Saf; 2021 May; 44(5):565-579. PubMed ID: 33575980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia.
    Haddad C; Salameh P; Sacre H; Clément JP; Calvet B
    BMC Psychiatry; 2023 Jan; 23(1):61. PubMed ID: 36694187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span.
    Khan WU; Ghazala Z; Brooks HJ; Subramaniam P; Mulsant BH; Kumar S; Voineskos AN; Blumberger DM; Kern RS; Rajji TK
    Schizophr Bull; 2021 Jan; 47(1):249-257. PubMed ID: 32619225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs.
    Brébion G; Bressan RA; Amador X; Malaspina D; Gorman JM
    Psychol Med; 2004 Feb; 34(2):369-74. PubMed ID: 14982143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.